Clinical Trial

Molecular Signatures of Cutaneous Dupilumab Response

Name: Molecular Signatures of Cutaneous Dupilumab Response — clinical trial record (NCT05858619)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 4

View on ClinicalTrials.gov →

Summary

This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.

Protocol Amendment History 2 amendments

This ClinicalTrials.gov record has been amended 2 times since 2023-05-04; most recent amendment 2026-06-01.

Trial Details

NCT Number	NCT05858619
Lead Sponsor	University of California, San Francisco
Conditions	Atopic Dermatitis
Enrollment	15 participants
Start Date	2023-02-01
Primary Completion	2028-02-01 (estimated)
Study Completion	2028-02-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-04